0001104659-23-112633 8-K 13 20231030 8.01 9.01 20231030 20231030 Annovis Bio, Inc. 0001477845 2834 262540421 DE 1231 8-K 34 001-39202 231361477 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 QR Pharma, Inc. 20091202 8-K 1 tm2329368d2_8k.htm FORM 8-K
0001477845 false 0001477845 2023-10-30 2023-10-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): October 30, 2023

 

 

 

ANNOVIS BIO, INC.

(Exact Name of Registrant as Specified in Charter) 

 

 
     
Delaware 001-39202 26-2540421

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

 

1055 Westlakes Drive, Suite 300
Berwyn, PA 19312

(Address of Principal Executive Offices, and Zip Code)

 

(610) 727-3913

Registrant’s Telephone Number, Including Area Code

 

                       Not Applicable                       

(Former Name or Former Address, if Changed Since Last Report) 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share ANVS New York Stock Exchange

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

Item 8.01 Other Events.

 

On October 30, 2023, the Company issued a press release announcing the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase 2/3 trial of buntanetap, a drug candidate for moderate to mild Alzheimer’s Disease patients. A copy of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)    Exhibits

 

Exhibit
Number

 

Description

99.1   Press Release, dated October 30, 2023.
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).
     

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ANNOVIS BIO, INC.
     
Date: October 30, 2023 By:

/s/ Henry Hagopian, III

    Name: Henry Hagopian, III
    Title: Chief Financial Officer

 

 

 

EX-99.1 2 tm2329368d2_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1 

 

ANNOVIS BIO RECEIVES POSITIVE RECOMMENDATION TO CONTINUE PHASE 2/3 TRIAL OF BUNTANETAP FOR alzheimer’S DISEASE PATIENTS FROM THE INDEPENDENT DATA AND SAFETY MONITORING BOARD (DSMB)

 

BERWYN, PENNSYLVANIA -- October 30, 2023 (BUSINESS WIRE)-- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase 2/3 trial of buntanetap, a drug candidate for moderate to mild Alzheimer’s Disease (AD) patients. The DSMB recommended that Annovis continue the trial as originally designed.

 

The feedback from the DSMB was:

 

1.no drug-related SAEs (Serious Adverse Events)

 

2.each AE (Adverse Event): less than 5 percent

 

3.very low dropout rate: 4.7 percent

 

“The findings from the DSMB are yet another positive affirmation for the direction we are taking in our research”, said Maria Maccecchini, Ph.D., CEO of Annovis. “We believe they are an important step along the way to potentially treating Alzheimer’s Disease.”

 

Annovis initiated the trial of buntanetap in late March 2023. The DSMB safety evaluation was set to occur when 90 patients completed 6 weeks of dosing. When the DSMB was convened on October 18, 2023, the data from a total of 107 patients was evaluated.

 

To date we have recruited a total of 281 patients out of the planned 320 patients; 76 patients have finished the study.

 

In our Alzheimer’s Disease phase 2 trials, buntanetap was observed to improve cognition and speed of thinking. It was easily administered as a single pill taken once daily and was generally well-tolerated.

 

About the Phase II/III Trial

 

This study is a phase 2/3, randomized, double-blind, placebo-controlled trial investigating the efficacy, safety, and tolerability of buntanetap for mild to moderate AD patients on top of their standard of care. Buntanetap (formerly known as Posiphen or ANVS401) attacks neurodegeneration by reducing multiple neurotoxic proteins, thereby improving synaptic transmission and axonal transport, which is the information highway of the nerve cell. Dysfunction of synaptic transmission and axonal transport has been shown to be the cause of nerve cell degeneration and ultimately death. Unlike other AD drugs in development which attempt to remove only one toxic protein, buntanetap inhibits several toxic proteins before they can form, thereby preventing the formation of all the major neurotoxic proteins responsible for PD and AD.

 

 

 

 

# # #

 

About Annovis Bio, Inc.

 

Headquartered in Berwyn, Pa., Annovis Bio, Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and other chronic neurodegenerative diseases. It is believed to be the only company developing a drug for both AD and PD designed to inhibit more than one neurotoxic protein to restore axonal and synaptic activity. By improving brain function, the company’s goal is to treat memory loss and dementia associated with AD as well as body and brain dysfunction associated with PD. For information about the company’s clinical trials and patents, visit anovisbio.com, and follow the company on LinkedIn and Twitter.

 

Forward-Looking Statements

 

This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company advises caution in reliance on forward-looking statements. Forward-looking statements include, without limitation, the Company's plans related to clinical trials. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those implied by forward-looking statements, including regarding patient enrollment, the safety or effectiveness of buntanetap and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety and tolerability of buntanetap. See also additional risk factors set forth in the Company's periodic filings with the SEC, including, but not limited to, those risks and uncertainties listed in the section entitled "Risk Factors," in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC. All forward-looking statements in this press release are based on information available to the Company as of the date of this filing. The Company expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

 

Investor Contact:

 

Maria Maccecchini

 

 

 

 

 

EX-101.SCH 3 anvs-20231030.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 anvs-20231030_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 anvs-20231030_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Oct. 30, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 30, 2023
Entity File Number 001-39202
Entity Registrant Name ANNOVIS BIO, INC.
Entity Central Index Key 0001477845
Entity Tax Identification Number 26-2540421
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1055 Westlakes Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Berwyn
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19312
City Area Code 610
Local Phone Number 727-3913
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ANVS
Security Exchange Name NYSE
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
XML 7 tm2329368d2_8k_htm.xml IDEA: XBRL DOCUMENT 0001477845 2023-10-30 2023-10-30 iso4217:USD shares iso4217:USD shares 0001477845 false 8-K 2023-10-30 ANNOVIS BIO, INC. DE 001-39202 26-2540421 1055 Westlakes Drive Suite 300 Berwyn PA 19312 610 727-3913 Common Stock, par value $0.0001 per share ANVS NYSE false false false false true true EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://annovisbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports anvs-20231030.xsd anvs-20231030_lab.xml anvs-20231030_pre.xml tm2329368d2_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2329368d2_8k.htm": { "nsprefix": "ANVS", "nsuri": "http://annovisbio.com/20231030", "dts": { "schema": { "local": [ "anvs-20231030.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "anvs-20231030_lab.xml" ] }, "presentationLink": { "local": [ "anvs-20231030_pre.xml" ] }, "inline": { "local": [ "tm2329368d2_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://annovisbio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-10-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2329368d2_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2329368d2_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001104659-23-112633-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-112633-xbrl.zip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end